Models of pig-to-baboon xenografting were examined to identify the mechanisms and pathologic characteristics of acute humoral xenograft rejection (AHXR). Thymus and kidney (composite thymokidney) from human decay accelerating factortransgenic swine were transplanted into baboons (n ‫؍‬ 16) that were treated with an immunosuppressive regimen that included extracorporeal immunoadsorption of anti-␣Gal antibody and inhibition of complement activation. Morphologic and immunohistochemical studies were performed on protocol biopsies and graftectomy samples. All renal xenografts avoided hyperacute rejection. However, graft rejection coincided with the increase of anti-␣Gal antibody in the recipient's circulation. The 16 xenografts studied were divided into two groups dependent on the rapid return (group 1) or gradual return (group 2) of anti-␣Gal antibody after immunoadsorption. In group 1 (n ‫؍‬ 6), grafts were rejected to day 27 with development of typical AHXR, characterized by marked interstitial hemorrhage and thrombotic microangiopathy in the renal vasculature. In group 2 (n ‫؍‬ 10), grafts also developed thrombotic microangiopathy affecting mainly the glomeruli by day 30 but also showed minimal evidence of interstitial injury and hemorrhage. In the injured glomeruli, IgM and C4d deposition, subsequent endothelial cell death and activation with upregulation of von Willebrand factor and tissue factor, and a decrease of CD39 expression developed with the formation of fibrin-platelet multiple microthrombi. In this model, the kidney xenografts, from human decay accelerating factor-transgenic swine, in baboons undergo AHXR. In slowly evolving AHXR, graft loss is associated with the development of thrombotic microangiopathic glomerulopathy. Also, anti-␣Gal IgM deposition and subsequent complement activation play an important role in the mechanism of glomerular endothelial injury and activation and the formation of multiple microthrombi.
X enotransplantation has the potential to provide a solution to the critical shortage of organs for transplantation in humans (1, 2) . Swine have been proposed as a suitable donor species because of their anatomic and physiologic similarities to human organs and the ability of graft survival to be facilitated by modification of the donor by genetic engineering (2) (3) (4) . When porcine organs are transplanted into primates, at least two major immunologic barriers need to be overcome in order for xenotransplants to be successful. The first major immunologic barrier is hyperacute rejection. The second major barrier is acute humoral xenograft rejection (AHXR), also known as acute vascular rejection or delayed xenograft rejection. This entity has become the most significant barrier to successful xenotransplantation (5) (6) (7) (8) (9) .
In the past decade, the development of genetically modified pigs that are transgenic for human complement regulatory proteins, such as human decay accelerating factor (hDAF), membrane co-factor protein (MCP; CD46), and CD59 (protectin), have been studied. Expression of these transgenesassociated proteins contributes to the inhibition of complement activation, leading to overcoming the problem of hyperacute rejection and prolongation of graft survival in primates (10 -15) . Our laboratory has tested tolerance induction strategies using donor thymic grafts (16 -19) and reported that composite thymus and kidney (thymokidney) xenotransplantation from hDAF-transgenic swine to baboons induce in vitro donor-specific T cell unresponsiveness and stable anti-galactose ␣1-3 galactose (␣Gal) antibody levels (20) . In this model, the cellular mechanism involving xenograft rejection could be controlled. Also, anti-␣Gal antibody returned slowly and gradually after immunoadsorption. Unfortunately, hDAF-transgenic grafts are still rejected, with the return of the xenoreactive natural antibodies to ␣Gal after immunoadsorption. The analysis of the xenografts in this model provided us with an excellent system to identify the mechanisms and pathologic characteristics of AHXR in kidney xenografts, particularly in mild but persistent antibody-mediated rejection and without appreciable components of T cell-mediated rejection.
This study examined the morphologic and immunohistochemical characteristics of AHXR, using serial biopsies from hDAF-transgenic swine renal xenografts. We focused on antibody, complement activation, endothelial cell injury and activation, platelet accumulation, and fibrin thrombi formation inducing graft loss in AHXR.
Materials and Methods

Animals
Male or female recipient baboons (Papio anibus; n ϭ 16) that weighed between 8 and 20 kg were purchased from Biologic Resources Foundation (Houston, TX). Transplant donors were provided by Novartis (East Hanover, NJ) from their herd of Landrace swine transgenic for hDAF. All experiments were performed in accordance with NIH Guidelines for Care and Use of Laboratory Animals, and were approved by the Massachusetts General Hospital Subcommittee on Research Animal Care.
Transplantation and Immunosuppression
Composite thymokidney grafts were prepared in hDAF-transgenic swine by the autologous implantation of thymic tissue under the renal capsule 6 to 8 wk before transplantation, as described previously (19, 20) . The surgical techniques of harvesting donor organs, recipient thymectomy, splenectomy, and kidney transplantation have been described previously (20 -22) , as have details of supportive care. Baboons were subjected to a right nephrectomy, but the ureter of a left kidney was kept patent to maintain renal function in case of failure of the thymokidney or graftectomy at later times. Monitoring of anti-␣Gal antibody levels in the recipient circulation was determined by ELISA (23, 24) .
Antibody depletion from the nonhuman primate was achieved by extracorporeal immunoadsorption by perfusing plasma through columns that contained synthetic
Gal type VI trisaccharide; AL Research Council, Edmonton, AL, Canada) over 3 d as described previously (22) (23) (24) .
The tolerance induction and immunosuppression regimen previously described from this laboratory for pig-to-primate xenotransplantation was used (20 -22,25,26) . All recipients underwent a tolerance induction regimen and extracorporeal immunoadsorption before composite thymokidney transplantation on day 0. The tolerance induction regimen using donor thymus transplantation consisted of (1) thymectomy (day Ϫ14) or thymic irradiation (700 cGy; day Ϫ1); (2) T cell depletion using anti-thymocyte globulin (ATG; ATGAM; Upjohn Co., Kalamazoo, MI) or anti-monkey CD3 antibody immunotoxin conjugate (FN18-CRM9; Neville, NIH, Bethesda, MD); and (3) splenectomy (day 0). In addition, recipients received continuous immunosuppression: (1) Mycophenolate mofetil (Roche, Nutley, NJ) at 110 mg/kg per d was started on day Ϫ7 and continued throughout the experiment, (2) cyclophosphamide (Mead Johnson Oncology Products, Princeton, NJ) was administered at 20 mg/kg starting on day Ϫ6 and continued to a maximum of 120 mg/kg for the duration of the experiment, (3) antihuman CD40 ligand (Immerge BioTherapeutics, Inc., Cambridge, MA) was administered at 20 mg/kg starting on day 0 and every other day thereafter, and (4) cobra venom factor (Immerge BioTherapeutics, Inc.) was administered twice daily at 200 to 400 U/kg and continued throughout the experiment to maintain CH 50 levels Ͻ5%.
Histologic and Immunohistochemical Examination
Kidney samples were taken from open kidney biopsy on postoperative day (POD) 15 and from nephrectomy at the time when animals died or demonstrated clinical evidence of graft rejection or systemic disseminated intravascular coagulation (DIC). For light microscopic examination, tissue was fixed in 10% buffered formalin and embedded in paraffin. Sections were examined after hematoxylin and eosin and periodic acid-Schiff staining. For electron microscopic studies, tissue was fixed in 2.5% glutaraldehyde in phosphate buffer (pH 7.4) and postfixed with 1% osmium tetroxide, dehydrated, and embedded in Epon 812. Ultrathin sections were stained with lead citrate and examined with a Phillips 301 electron microscope. For immunofluorescence studies for the detection of deposition of Ig, complement, and fibrinogen, frozen tissue sections were stained by the direct immunofluorescent technique, using FITC-conjugated rabbit polyclonal antibody to human IgG (1:30), IgM (1:20), C3 (1:10), and fibrinogen (1:20; all from DAKO, Carpinteria, CA), and the indirect immunofluorescent technique, using mouse anti-human C4d (Quidel, San Diego, CA), polyclonal rabbit anti-human C4d (American Research Products, Inc., Belmont, MA), and mouse anti-human C5b-9 (DAKO).
The following primary antibodies were used for immunohistochemistry to examine the characteristics of AHXR: (1) Monoclonal mouse anti-human CD55 (hDAF) antibody (clone BRIC 216; Biosource International, Camarillo, CA); (2) monoclonal mouse anti-swine CD31 platelet endothelial cell adhesion molecule 1 (PECAM1) antibody (Serotec, Raleigh, NC), which can detect capillary structure in swine xenografts; (3) polyclonal rabbit anti-tissue factor antibody (the cross-reactive antiporcine tissue factor antibody was kindly provided by Prof. Yale Nemerson, Mount Sinai School of Medicine, New York, NY) (27, 28) , which can detect the expression of tissue factor on activated endothelial cells in xenografts; (4) monoclonal mouse anti-pig CD39 antibody (29, 30) , which can detect the expression of ATP diphosphohydrolase (one of the thromboregulatory factor) on endothelial cells in xenografts; (5) monoclonal anti-human CD41 antibody (5B12; DAKO), which can detect the aggregation of baboon platelets in the grafts; and (6) polyclonal rabbit anti-human von Willebrand factor (vWF; DAKO), which can detect the vWF in endothelial cells and thrombi. For immunohistochemical staining of CD55, CD31, tissue factor, CD39, and CD41, frozen tissue sections were used and the specimens were stained by the standard avidin-biotin-peroxidase complex technique. To detect platelet-fibrin thrombi in xenografts, we performed double immunohistochemistry against CD41 (Texas Red) and fibrinogen (FITC). In addition, the relationship between CD41ϩ platelet aggregation and the deposition of Ig or complement was assessed by double immunohistochemistry against CD41 (Texas Red) and IgM (FITC) or C4d (FITC). In histologic sections, fragmented nuclear DNA associated with apoptosis was labeled by the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick endlabeling (TUNEL) method (31) .
Quantification of Histologic Findings
In each kidney sample, 40 randomly selected interstitial fields (0.065 mm 2 ) or 40 glomerular cross-sections were assessed at ϫ400 in each kidney sample, without previous knowledge of the clinical or histologic findings, for the following parameters: (1) Thrombotic microangiopathic glomerulopathy: the mean semiquantitative severity score of glomerulopathy, per glomerular cross-section in periodic acid-Schiffstained sections (scores 0 to 3: score 0, no glomerulopathy; score 1, segmental and mild glomerulopathy; score 2, segmental and moderate glomerulopathy; score 3, global and severe glomerulopathy); (2) 
Results
Experimental Group, Graft Survival, and hDAF Expression in the Grafts
Sixteen thymokidneys from hDAF-transgenic swine were transplanted into baboons. The serum anti-␣Gal antibody levels were examined in all recipients ( Figure 1 ). In this study, we divided the recipients into two groups depending on the manner of the return of the anti-␣Gal antibody after immunoadsorption. Group 1 was defined as the rapid and progressive return of anti-␣Gal IgM and/or IgG by POD 14. Six recipients were included in group 1 (Table 1) . Group 2 was defined as the slow and gradual return of IgM and IgG by POD 14. Ten recipients were included in group 2.
Of the 16 xenografts in groups 1 and 2, none underwent hyperacute rejection (Table 1) . In group 1, five of six grafts were lost before POD 14 by advanced AHXR (n ϭ 3) or systemic complications (n ϭ 2). Graftectomy for clinical features of graft rejection or systemic DIC was performed in two animals (POD 9 and 11). One graft survived until POD 27. In group 2 (n ϭ 10), graftectomy (n ϭ 3) with clinical findings of graft rejection or DIC was performed on POD 15, 18, and 20. Histologically, fully developed glomerulopathy was evident in six grafts that were taken after POD 14. One graft survived up to POD 30.
The degree of hDAF expression within the hDAF-transgenic kidney graft was examined by immunohistochemistry for CD55 ( Figure 2 ). In normal MGH miniature swine (34, 35) , no positive staining was detected within the kidneys (data not shown). In groups 1 and 2, before transplantation, there was a strong expression of CD55 in the renal vasculature, including the glomeruli, PTC, and arteries. However, as the AHXR advanced in groups 1 and 2, there was a recognizable loss of CD55 expression in the grafts.
Development of AHXR
In group 1, coinciding with the rapid and progressive return of anti-␣Gal antibody after immunoadsorption, graft rejection developed as early as POD 9 ( Table 1 ). The rejection process showed typical AHXR with marked interstitial hemorrhage, edema, and thrombotic microangiopathy in the PTC and glomeruli ( Figures 3A and 4 , A and B). Numerous TUNELϩ dead cells were detected in both the PTC and glomeruli, but minimal in the arteries ( Figures 3B and 4 , C and D). An increase of tissue factor expression and a decrease of CD39 expression were seen on endothelial cells in both the PTC and glomeruli ( Figure 5 , B and C). Destruction of the capillary network of the PTC and glomeruli was detected by loss of CD31ϩ capillaries ( Figure  5D ). CD41ϩ platelet aggregation was evident in both the PTC and glomeruli ( Figure 5A ). Through immunofluorescent analysis of the xenografts, IgM and C4d deposits were revealed in both the PTC and glomeruli ( Figure 3, C and D) . No IgG deposition but C3 and C5b-9 deposition was detected weakly in both the PTC and glomeruli.
In group 2, coinciding with the delayed return of anti-␣Gal antibody after immunoadsorption, AHXR developed slowly and gradually. The morphology of AHXR in group 2 was different from group 1. During early AHXR on POD 15, focal and segmental glomerulopathy was seen with almost intact interstitium and small arteries ( Figure 3E ). A few TUNELϩ dead cells were evident in the glomeruli but were minimal in the PTC, arteries, and tubules ( Figure 3F ). Through immunohistochemistry, there was some evidence of focal IgM and C4d deposits in the glomeruli (Figure 3 , G and H). However, these Ig and complement depositions could not be detected in the PTC or small arteries. There was no evidence of IgG and minimal C3 and C5b-9 deposition in the grafts, mainly in the glomeruli. Apparently, the glomeruli were the first area of localization of anti-␣Gal antibody deposition and complementmediated graft injuries in AHXR.
As the rejection progressed, there was more diffuse, global, and moderate to severe thrombotic microangiopathic glomerulopathy present in all of the graftectomy samples (n ϭ 3; POD 15, 18, and 20) and in the grafts with relatively long-term survival (POD 14, 16, 27, and 30; Figures 3I and 4A) . However, the interstitium showed minimal injuries, with no or minimal interstitial hemorrhage or edema ( Figure 4B ). The amount of Figure 1 . Circulating natural anti-galactose ␣1-3 galactose (␣Gal) IgM and IgG levels in recipients by postoperative day (POD) 14 in group 1 (n ϭ 6) and group 2 (n ϭ 10). Group 1 is defined as the rapid and progressive return of anti-␣Gal IgM and/or IgG after removal of antibodies by extracorporeal immunoabsorption. Group 2 is defined as the slow and gradual return of anti-␣Gal IgM and IgG. Results were indicated by mean Ϯ SE.
TUNELϩ cells and CD41ϩ platelets had increased within the glomeruli but minimally in the PTC ( Figures 3J, 4, C and D, and  5E ). An increase of tissue factor expression and a decrease of CD39 expression and destruction of the capillary network were evident within mainly the glomeruli but minimally in the PTC and arteries ( Figure 5, F through H) . The IgM and C4d depo- Figure 2 . Expression of the human decay accelerating factor (hDAF; CD55) in renal xenografts from hDAF-transgenic swine before transplantation and during the development of acute humoral xenograft rejection (AHXR). (A) Strong expression of CD55 was evident on the glomeruli (arrow) and moderate expression on peritubular capillaries (PTC) and small arteries (arrowhead) before transplantation on POD 0. (B) At the time when AHXR fully developed in the grafts in group 1, CD55 expression was lost diffusely on the glomeruli (arrow), PTC, and the small arteries (arrowhead; group 1, #4, POD 12). (C) In the grafts with mild AHXR on POD 15 (taken at a similar time point as group 1) in group 2 (#16), a focal and segmental decrease of CD55 expression was detected on the glomeruli (arrow), PTC, and small arteries (arrowhead). (D) When AHXR progressed in the grafts in group 2 (#16, POD 30), CD55 expression was lost diffusely on the glomeruli (arrow), PTC, and the small arteries (arrowhead). c Blood platelet counts and plasma fibrinogen levels were compared between levels from pre-Tx and day of death or graftectomy (post-Tx).
sition was diffuse throughout the glomeruli (Figure 3, K and L) . However, deposition of IgM and C4d was not detectable in the PTC. IgG still remained negative in the grafts. The deposition of C3 and C5b-9 was detected weakly within the glomeruli but not in the PTC.
During the development of AHXR and/or thrombotic microangiopathic glomerulopathy in renal xenografts, both the platelet counts in the peripheral blood and the plasma fibrinogen levels decreased in the baboons (Table 1) . Importantly, this decrease of platelets and fibrinogen in the blood seemed to be Figure 3 . Typical AHXR in group 1 (A through D), mild glomerulopathy on POD 15 biopsy in group 2 (E through H), and severe thrombotic microangiopathic glomerulopathy at nephrectomy in group 2 (I through L). Grafts in group 1 showed typical morphology of AHXR, characterized by the evidence of hemorrhage in the interstitium and diffuse thrombotic microangiopathic glomerulopathy (group 1, #4, POD 12). Numerous TUNELϩ dead cells (arrow), undergoing either apoptosis or necrosis, were seen in the glomeruli and PTC, even before the development of advanced AHXR (group 1, #3, POD 11). Marked IgM (C) and C4d (D) deposition was detected in a diffuse pattern in both the glomeruli and PTC (group 1, #5, POD 13). In contrast, grafts of group 2 on POD 15 biopsy (#16; E) showed focal and segmental thrombotic microangiopathic glomerulopathy without interstitial hemorrhage. Grafts of group 2 at nephrectomy (#16, POD 30; I) showed diffuse and global thrombotic microangiopathic glomerulopathy without obvious arterial, tubular, or interstitial injuries. Although TUNELϩ dead cells (arrow) were evident in the glomeruli on POD 15 (F) and on POD 30 (J) in group 2, these cells in the PTC remained minimal. In group 2, IgM (G and K) and C4d (H and L) deposition was present in only the glomeruli in a focal pattern on POD 15 (G and H) and a diffuse pattern on POD 30 (K and L). However, they could not be detected in the PTC or small arteries. Magnification, ϫ200 in A, E, and I (hematoxylin and eosin stain); ϫ400 in B, F, and J (terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling [TUNEL] stain); ϫ200 in C, G, and K (IgM stain); ϫ200 in D, H, and L (C4d stain). associated with glomerular injury but not with PTC injury (Figure 4, E and F) .
Only rarely were interstitial mononuclear cells detected and no or little tubulitis was observed in xenografts through the progression of AHXR. These observations may be associated with the in vitro donor-specific T cell unresponsiveness obtained in the recipients in our model of co-transplantation of the thymus plus kidney. There was some neutrophil infiltration, associated with the development of antibody-mediated rejection.
Endothelial Cell Death and Activation in Thrombotic Microangiopathic Glomerulopathy
Although thrombotic microangiopathy developed in the PTC and glomeruli in typical AHXR, thrombotic microangiopathy that affected only the glomeruli (thrombotic microangiopathic glomerulopathy) was a characteristic feature in early or slowly evolving AHXR. Importantly, only thrombotic microangiopathic glomerulopathy could induce graft loss and the clinical features of systemic DIC, if it was fully developed ( Table 1) . We Figure 4 . The degree of thrombotic microangiopathic glomerulopathy (A), interstitial hemorrhage (B), and the number of TUNELϩ dead cells in glomeruli (C) and PTC (D) in groups 1 (E) and 2 (F) and at certain time points throughout the course. Also, the correlation between the platelet counts in peripheral blood (E) or plasma fibrinogen levels (F) and the degree of glomerular or interstitial injuries. In group 1, the grafts were characterized by the development of glomerulopathy together with the interstitial hemorrhage. TUNELϩ dead cells were also prominent in both the glomeruli and PTC. By contrast, in group 2, severe thrombotic microangiopathic glomerulopathy with TUNELϩ glomerular cells developed. However, interstitial hemorrhage and TUNELϩ dead cells in the PTC were minimal in group 2, compared with in group 1, indicating that mild and persistent AHXR may contribute less to PTC injury. The platelet counts and plasma fibrinogen levels were associated with glomerular injury (observed through the severity of glomerulopathy and the number of TUNELϩ dead glomerular [G] cells) but not associated with the interstitial injuries (observed through the severity of interstitial hemorrhage and the number of TUNELϩ dead PTC cells). assessed the mechanism of thrombotic microangiopathic glomerulopathy because it should be avoided for long-term graft acceptance. The progression of the thrombotic microangiopathic glomerulopathy observed in group 2 was followed in POD 15 biopsy and graftectomy tissues (Figures 6 through 8) . The multiple thrombi seen in the glomerulopathy were charac-
Figure 5. Aggregation of platelets (A and E), the expression of tissue factor (B and F), the decrease of CD39 expression (C and G), and destruction of capillary network (D and H) in the grafts in groups 1 (A through D) and 2 (E through H).
In grafts in group 1, platelet-fibrin thrombi, endothelial cell activation with the expression of tissue factor and a decrease of CD39 expression, and destruction of capillary network were evident in both the PTC and glomeruli (A: group 1, #1, POD 9; B and C: group 1, #5, POD 13; D: group 1, #6, POD 27). In grafts in group 2, platelet-fibrin thrombi, endothelial cell activation with the expression of tissue factor and decrease of CD39 expression, and destruction of capillary network were detected mainly within glomeruli but minimally in the PTC (E: group 2, #11, POD 15; F: group 2, #13, POD 18; G and H: group 2, #15, POD 27). Magnification, ϫ100 in A and E (CD41 stain), B and F (tissue factor stain), C and G (CD39 stain), and D and H (CD31 stain). terized by platelet-fibrin thrombi ( Figure 6, A and B) . Furthermore, multiple microthrombi were present in glomerular capillaries that had undergone extensive deposition of IgM and C4d ( Figure 6 , C and D), indicating that IgM and subsequent complement activation could mediate thrombotic changes in damaged glomeruli. The glomerular changes in light microscopy were characterized by a loss of capillary lumen, decreased cellularity, expansion of mesangial matrix, and exudative changes ( Figure 7 , A through C). The first glomerular lesions were present in a segmental pattern in the POD 15 biopsy. As AHXR progressed, these changes increased to an almost global pattern in the glomeruli with multiple microthrombi at nephrectomy (POD 14 to 30). These same time points follow glomerular cell death assessed by the TUNEL method ( Figure  7, D through F) . TUNELϩ dead cells were present in the glomeruli before thrombotic microangiopathic glomerulopathy could be diagnosed morphologically on POD 7. The number of these cells increased during the development of glomerulopathy. The capillary network in the glomeruli was examined, as seen in the CD31 stain ( Figure 7 , G through I). During the development of glomerulopathy, the CD31ϩ glomerular capillary network gradually became destroyed.
The progression of thrombotic microangiopathic glomerulopathy was followed through the expression of vWF, tissue factor, CD39, and CD41 (Figure 8 ). vWF and tissue factor became prominent in the glomeruli; as glomerulopathy progressed, a decreased expression of CD39 in the glomeruli was also observed, as well as CD41ϩ platelet aggregation. The same glomerular features occurred in group 1.
The development of thrombotic microangiopathic glomerulopathy and an increase of TUNELϩ dead glomerular cells correlated strongly with the deposition of IgM and C4d in the glomeruli (Figure 9, A through D) . This suggests that anti-␣Gal IgM deposition and the subsequent complement activation play an important role in the major mechanism of the development of glomerulopathy. We also observed that complement deposition seemed to be associated with loss of CD55 (hDAF) expression in hDAF-transgenic kidney grafts ( Figure 9E ). In Figure 7 . Development of thrombotic microangiopathic glomerulopathy on POD 7 (group 2, #8; A, D, and G), POD 15 (group 2, #16; B, E, and H), and POD 30 (group 2, #16; C, F, and I) in group 2. (A through C) The thrombotic microangiopathic glomerulopathy was characterized by a loss of capillary lumen, decreased cellularity, expansion of mesangial matrix, and exudative changes. The early glomerular lesions were present in a segmental pattern on POD 15 (arrow) and increased to an almost global pattern in the glomeruli with multiple microthrombi by POD 30. (D through F) TUNELϩ dead cells (arrow) were present in the glomerular capillary lumen, and the number of these cells increased during the development of glomerulopathy by POD 30. (G through I) CD31 platelet endothelial cell adhesion molecule 1 (PECAM1) can be used to visualize glomerular endothelial cells. During the development of glomerulopathy, the CD31ϩ glomerular capillary network was gradually destroyed. Magnification, ϫ600 in A through C (periodic acid-Schiff stain), D through F (TUNEL stain), and G through I (CD31 stain).
addition, the severity of glomerulopathy correlated strongly with the following: Decrease of CD55 expression, increase of TUNELϩ dead cells, loss of CD31ϩ glomerular capillaries, increase of vWF and tissue factor, decrease of CD39 expression of endothelial cells, and finally CD41ϩ platelet aggregation within the glomeruli (Figure 9 , F through L). The extent of CD41ϩ platelet aggregation in the glomeruli was also strongly correlated with the number of TUNELϩ cells, the degree of vWF and tissue factor expression, or the decrease in CD39 expression in the glomeruli (Figure 9 , M through P). These findings indicate that thrombotic microangiopathic glomerulopathy, with multiple fibrin-platelet thrombi, may be ascribed to both endothelial cell death and endothelial cell activation.
The xenografts were also examined morphologically through electron microscopy ( Figure 10 ). Both endothelial cell death and activation with fibrin deposition were fundamental findings of thrombotic microangiopathic glomerulopathy. In the severely damaged glomeruli, the glomerular capillary network was destroyed with fibrin deposition.
Discussion
In this study, we show that typical AHXR develops in hDAFtransgenic kidneys and that this is associated with the increases in anti-␣Gal antibody levels in recipients after the termination of immunoadsorption. In the slow, gradual development of AHXR, the morphology of the renal xenograft differs from the typical AHXR. This variant is characterized by thrombotic microangiopathic glomerulopathy with minimal PTC injury and interstitial hemorrhage. Here, IgM and complement deposition in the glomeruli, with both endothelial cell death and activation, are associated with the formation of fibrin-platelet thrombi inducing graft loss.
We previously demonstrated using normal MGH miniature swine organs that were transplanted into primates that AHXR develops, facilitated by anti-␣Gal antibody and complement activation, resulting in graft failure within 2 wk (22, 36, 37) . The renal microvascular injury to the glomeruli and PTC develops in AHXR and is characterized by thrombotic microangiopathy in the glomeruli and PTC with diffuse interstitial hemorrhage (36, 37) . In our study, group 1, which had a rapid return of circulating anti-␣Gal antibody after immunoadsorption, developed similar morphologic features of AHXR from POD 9 to POD 27 even in the hDAF kidney grafts. However, group 2, which had a delayed return of circulating anti-␣Gal antibody, developed histopathologic features that were different from those previously described. Microvascular injury with endothelial cell death and activation was prominent within the glomeruli and less involved in the PTC. The characteristic morphologic feature was thrombotic microangiopathic glomerulopathy with minimal evidence of interstitial hemorrhage. The mecha- Figure 9 . The relationship between the severity of thrombotic microangiopathic glomerulopathy and several morphologic parameters. F, group 2; E, group 1. (A through E) The degree of IgM and/or C4d deposition was correlated with the degree of glomerulopathy, the number of TUNELϩ glomerular cells, and a decrease of CD55 expression in the glomeruli. (F through H) The severity of thrombotic microangiopathic glomerulopathy was strongly associated with the decrease of CD55 (hDAF) expression, the increase of TUNELϩ glomerular cells, and loss of glomerular capillaries. (I through L) The severity of glomerulopathy was also associated with the increase of vWF deposition, tissue factor expression, and platelet deposition and the decrease CD39 expression. (M through P) A correlation between the amount of CD41ϩ platelet aggregation and the number of TUNELϩ cells, the degree of vWF deposition, tissue factor expression, or decrease of CD39 expression in the glomeruli was evident.
nism of less prominent PTC injury and interstitial hemorrhage in slowly evolving AHXR is uncertain. However, several hypotheses are considered. The small amount of anti-␣Gal antibody is absorbed within the glomeruli which express the ␣Gal antigen, before the plasma perfuses the PTC, and/or reacted antibody and complements on endothelial cells can be eliminated more rapidly and strongly in PTC than in glomerular capillaries in the renal xenografts. In support of these hypotheses, the deposition of IgM and C4d was detected within only the glomeruli in group 2. It is also possible that the accommodation phenomenon can develop more strongly in PTC than in glomerular capillaries in renal xenografts.
The diagnosis of early or mild AHXR is important to attempt to prevent graft failure. Our results suggest that the effects of early or mild AHXR can induce morphologic changes within the renal xenograft that are different from the usual pattern of humoral rejection in human allografts. In the diagnosis of xenograft rejection, thrombotic microangiopathic glomerulopathy without interstitial hemorrhage could be recognized as a milder, nonthreatening form of rejection in routine light microscopy. However, it is important to realize that xenografts are frequently lost with clinical features of systemic DIC by only thrombotic microangiopathic glomerulopathy, once this is fully developed.
A recent study using cardiac xenotransplantation demonstrated that acute vascular rejection is caused mainly by endothelial cell activation and not by apoptosis in the endothelium; and the deposition of fibrin always precedes the appearance of apoptotic endothelial cells (38) . In our study, however, in glomeruli with thrombotic microangiopathy, numerous TUNELϩ dead cells were detected with the destruction of the glomerular capillary network. In addition, the first abnormality recognized in the renal xenografts was endothelial labeling by the TUNEL method in the glomeruli, before AHXR or glomerulopathy could be diagnosed morphologically in this model. This discrepancy between cardiac and renal xenografts may be dependent on organ specificity or the differing conditioning regimens. In cardiac xenografts, anti-␣Gal antibody can react diffusely on cardiac microvasculature that can induce mainly endothelial cell activation before undergoing cell death. By contrast to cardiac xenografts, a small amount of anti-␣Gal antibody reacts mainly within the glomeruli (small capillary area) in the kidney graft, and concentrated antibody in glomeruli can induce apoptosis and necrosis in glomerular endothelial cells. Endothelial cell death can cause the loss of vascular integrity, and it deprives the endothelium of normal function, such as the inhibition of coagulation and inflammation (39 -42) . Also, capillary destruction can cause exposure of the matrix to coagulation in the blood. Endothelial cell death and subsequent capillary destruction in glomerulopathy, therefore, are important causes of multiple fibrin-platelet thrombi, inducing graft loss.
In glomeruli with thrombotic microangiopathy, endothelial cell activation also developed with an increase in vWF and tissue factor expression and an associated decrease in CD39 expression. The involvement of endothelial cell activation in the pathogenesis of AHXR is supported by several studies (38, (43) (44) (45) . Tissue factor, the major initiator of coagulation in vivo, is a 45-kD cell membrane glycoprotein that acts as a cell surface receptor for factor VII and is directly in contact with coagulation factors in the blood (27, 28, 44, 46) . CD39 thromboregulatory factor, an NTP diphosphohydrolase, is expressed by quiescent endothelial cells and has the capacity to degrade the extracellular inflammatory mediators ATP and ADP to AMP, thereby inhibiting platelet activation and modulating vascular thrombosis (29, 30, 42) . Endothelial cell activation that leads to the upregulation of vWF and tissue factor and a decrease of CD39 expression in microangiopathic glomerulopathy may contribute to multiple fibrin-platelet thrombi. In this study, the number of glomerular dead cells and as well as the increase in expression of vWF and tissue factor and the decrease in CD39 expression were strongly correlated with the degree of fibrinplatelet thrombi.
The kidney grafts from hDAF-transgenic swine in this study showed strong expression of hDAF on the renal vasculature. The degree of hDAF expression in grafts before transplantation inversely correlates with the severity of AHXR after transplantation (47) . In addition, hDAF expression decreases during AHXR. Our study also showed that the expression of the CD55 (hDAF) was lost during the development of AHXR. The loss of CD55 expression in glomeruli strongly correlated with the deposition of C4d in glomeruli and the severity of glomerulopathy. These findings suggest that the decrease of hDAF expression after transplantation may contribute to the development of thrombotic microangiopathic glomerulopathy as well as AHXR. The loss of CD55 may be associated with the anti-␣Gal antibody and complement deposition on the vasculature and/or tissue injury and endothelial cell destruction in the grafts as the rejection progressed.
In this model, thrombotic microangiopathic glomerulopathy and graft loss coincided with the return of anti-␣Gal antibody in the recipients after immunoadsorption. Even in hDAF-transgenic kidney grafts, thrombotic microangiopathic glomerulopathy developed with IgM and C4d deposition in the glomeruli. It is possible that this glomerulopathy and graft loss may be prevented or modulated by elimination of humoral responses caused by the presence of anti-␣Gal antibody. Complete elimination of anti-␣Gal antibody is very difficult in usual immunosuppression therapy or immunoadsorption. However, an answer to this possibility may be forthcoming in the transplantation of truly ␣Gal-negative organs from pigs homozygous for ␣1,3-galactosyltransferase gene knockout (GalT-KO) (48, 49) , in which anti-␣Gal antibody-mediated rejection will be eliminated completely. Such studies are presently ongoing in our center using grafts from GalT-KO MGH miniature swine (50, 51) . In our initial experience, when baboons received our tolerance-inducing protocol including co-transplantation of a kidney plus vascularized thymic tissue, the kidney grafts from GalT-KO swine survived up to POD 83 in baboons with normal graft function and minimal thrombotic microangiopathic glomerulopathy (50) .
